| The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? RE Gilbert, ME Cooper Kidney international 56 (5), 1627-1637, 1999 | 889 | 1999 |
| Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children KA Nerenberg, KB Zarnke, AA Leung, K Dasgupta, S Butalia, K McBrien, ... Canadian Journal of Cardiology 34 (5), 506-525, 2018 | 751 | 2018 |
| Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. ME Cooper, D Vranes, S Youssef, SA Stacker, AJ Cox, B Rizkalla, ... Diabetes 48 (11), 2229-2239, 1999 | 692 | 1999 |
| Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children DM Rabi, KA McBrien, R Sapir-Pichhadze, M Nakhla, SB Ahmed, ... Canadian Journal of Cardiology 36 (5), 596-624, 2020 | 608 | 2020 |
| Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of … AA Leung, K Nerenberg, SS Daskalopoulou, K McBrien, KB Zarnke, ... Canadian Journal of Cardiology 32 (5), 569-588, 2016 | 581 | 2016 |
| Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial S Verma, CD Mazer, AT Yan, T Mason, V Garg, H Teoh, F Zuo, A Quan, ... Circulation 140 (21), 1693-1702, 2019 | 559 | 2019 |
| Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical … MA Pohl, S Blumenthal, DJ Cordonnier, F De Alvaro, G DeFerrari, ... Journal of the American Society of Nephrology 16 (10), 3027-3037, 2005 | 525 | 2005 |
| The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension SS Daskalopoulou, DM Rabi, KB Zarnke, K Dasgupta, K Nerenberg, ... Canadian Journal of Cardiology 31 (5), 549-568, 2015 | 503 | 2015 |
| Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults AA Leung, SS Daskalopoulou, K Dasgupta, K McBrien, S Butalia, ... Canadian Journal of Cardiology 33 (5), 557-576, 2017 | 458 | 2017 |
| The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension K Dasgupta, RR Quinn, KB Zarnke, DM Rabi, P Ravani, ... Canadian Journal of Cardiology 30 (5), 485-501, 2014 | 392 | 2014 |
| Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. RE Gilbert, A Cox, LL Wu, TJ Allen, UL Hulthen, G Jerums, ME Cooper Diabetes 47 (3), 414-422, 1998 | 367 | 1998 |
| Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy RE Gilbert, H Krum The Lancet 385 (9982), 2107-2117, 2015 | 348 | 2015 |
| Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition R Langham, D Kelly, A Cox, N Thomson, H Holthöfer, P Zaoui, N Pinel, ... Diabetologia 45, 1572-1576, 2002 | 333 | 2002 |
| Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease CD Mazer, GMT Hare, PW Connelly, RE Gilbert, N Shehata, A Quan, ... Circulation 141 (8), 704-707, 2020 | 327 | 2020 |
| The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2–therapy DG Hackam, NA Khan, BR Hemmelgarn, SW Rabkin, RM Touyz, ... Canadian Journal of Cardiology 26 (5), 249-258, 2010 | 326 | 2010 |
| Proximal tubulopathy: prime mover and key therapeutic target in diabetic kidney disease RE Gilbert Diabetes 66 (4), 791-800, 2017 | 322 | 2017 |
| Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy A Tzanidis, RD Hannan, WG Thomas, D Onan, DJ Autelitano, F See, ... Circulation research 93 (3), 246-253, 2003 | 315 | 2003 |
| The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension DG Hackam, RR Quinn, P Ravani, DM Rabi, K Dasgupta, ... Canadian Journal of Cardiology 29 (5), 528-542, 2013 | 309 | 2013 |
| Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale … SJ Haas, T Vos, RE Gilbert, H Krum American heart journal 146 (5), 848-853, 2003 | 303 | 2003 |
| The (Pro)Renin Receptor: Site-Specific and Functional Linkage to the Vacuolar H+-ATPase in the Kidney A Advani, DJ Kelly, AJ Cox, KE White, SL Advani, K Thai, KA Connelly, ... Hypertension 54 (2), 261-269, 2009 | 290 | 2009 |
